{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:56:29Z","timestamp":1775832989849,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Our study aims to summarize the clinical characteristics of rare types of congenital adrenal hyperplasia (CAH) other than 21-hydroxylase deficiency (21-OHD), and to explore the clinical applications of genetic analysis and liquid chromatography tandem-mass spectrometry (LC-MS\/MS) in rare CAH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analysed the clinical data of 5 rare cases of CAH admitted to our hospital and summarized their clinical manifestations, auxiliary examinations, diagnosis and mutational spectrum.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After gene sequencing, complex heterozygous variants were detected in all patients (2 cases were lipoid congenital adrenal hyperplasia (LCAH), 11\u03b2-hydroxylase deficiency (11\u03b2-OHD), 3\u03b2-hydroxysteroid dehydrogenase deficiency (3\u03b2-HSD deficiency) and P450 oxidoreductase deficiency (PORD) each accounted for 1 case), which were consistent with their clinical manifestations. Among them, 4 <jats:italic>novel<\/jats:italic> variants were detected, including c.650\u2009+\u20092\u2009T\u2009&gt;\u2009A of the <jats:italic>StAR<\/jats:italic> gene, c.1145\u2009T\u2009&gt;\u2009C (p. L382P) of the <jats:italic>CYP11B1<\/jats:italic> gene, c.1622C\u2009&gt;\u2009T (p. A541V) and c.1804C\u2009&gt;\u2009T (p. Q602 *) of the <jats:italic>POR<\/jats:italic> gene. The LC-MS\/MS results for steroid hormones in patients were also consistent with their genetic variants: 2 patients with LCAH showed a decrease in all steroid hormones; 11\u03b2-OHD patient showed a significant increase in 11-deoxycortisol and 11-deoxycorticosterone; patient with 3\u03b2-HSD deficiency showed a significant increase in DHEA; and PORD patient was mainly characterized by elevated 17OHP, progesterone and impaired synthesis of androgen levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The clinical manifestations and classification of CAH are complicated, and there are cases of missed diagnosis or misdiagnosis. It\u2019s necessary to combine the analysis of clinical manifestations and auxiliary examinations for diagnosis; if necessary, LC-MS\/MS analysis of steroid hormones or gene sequencing is recommended for confirming diagnosis and typing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00901-8","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T13:02:53Z","timestamp":1637845373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical applications of genetic analysis and liquid chromatography tandem-mass spectrometry in rare types of congenital adrenal hyperplasia"],"prefix":"10.1186","volume":"21","author":[{"given":"Zhuoguang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiqi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"issue":"8","key":"901_CR1","first-page":"569","volume":"54","author":"ML Du","year":"2016","unstructured":"Du ML. Consensus statement on diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency (Chinese). Zhonghua Erke Zazhi. 2016;54(8):569\u201376.","journal-title":"Zhonghua Erke Zazhi"},{"issue":"11","key":"901_CR2","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/jc.2018-01865","volume":"103","author":"PW Speiser","year":"2018","unstructured":"Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043\u201388.","journal-title":"J Clin Endocrinol Metab"},{"key":"901_CR3","doi-asserted-by":"crossref","unstructured":"Li Z, Huang L, Du C, Zhang C, Zhang M, Liang Y; et al. Analysis of the Screening Results for Congenital Adrenal Hyperplasia Involving 7.85 Million Newborns in China: A Systematic Review and Meta-Analysis.2021; 12:365.","DOI":"10.3389\/fendo.2021.624507"},{"issue":"10108","key":"901_CR4","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/S0140-6736(17)31431-9","volume":"390","author":"D El-Maouche","year":"2017","unstructured":"El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. 2017;390(10108):2194\u2013210.","journal-title":"Lancet"},{"issue":"2","key":"901_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.beem.2008.10.014","volume":"23","author":"N Krone","year":"2009","unstructured":"Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab. 2009;23(2):181\u201392.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"901_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jmoldx.2013.06.001","volume":"15","author":"Z Xu","year":"2013","unstructured":"Xu Z, Chen W, Merke DP, McDonnell NB. Comprehensive mutation analysis of the CYP21A2 gene: an efficient multistep approach to the molecular diagnosis of congenital adrenal hyperplasia. J Mol Diagn. 2013;15(6):745\u201353.","journal-title":"J Mol Diagn"},{"issue":"3","key":"901_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000337974","volume":"77","author":"N Janzen","year":"2012","unstructured":"Janzen N, Riepe FG, Peter M, Sander S, Steuerwald U, Korsch E, et al. Neonatal screening: identification of children with 11\u03b2-hydroxylase deficiency by second-tier testing. Horm Res Paediat. 2012;77(3):195\u20139.","journal-title":"Horm Res Paediat"},{"issue":"5","key":"901_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"5","key":"901_CR9","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1172\/JCI115182","volume":"87","author":"PC White","year":"1991","unstructured":"White PC, Dupont J, New MI, Leiberman E, Hochberg Z, R\u00f6sler A. A mutation in CYP11B1 (Arg-448----his) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest. 1991;87(5):1664\u20137.","journal-title":"J Clin Invest"},{"issue":"5205","key":"901_CR10","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1126\/science.7892608","volume":"267","author":"D Lin","year":"1995","unstructured":"Lin D, Sugawara T, Strauss JF 3rd, Clark BJ, Stocco DM, Saenger P, et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science. 1995;267(5205):1828\u201331.","journal-title":"Science."},{"key":"901_CR11","doi-asserted-by":"crossref","unstructured":"Tajima T, Fujieda K, Kouda N, Nakae J, Miller WL. Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab2001; 86(8):3820\u20133825.","DOI":"10.1210\/jcem.86.8.7748"},{"issue":"9427","key":"901_CR12","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(04)16503-3","volume":"363","author":"W Arlt","year":"2004","unstructured":"Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 2004;363(9427):2128\u201335.","journal-title":"Lancet"},{"issue":"6","key":"901_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1210\/mend-2-6-564","volume":"2","author":"M Kagimoto","year":"1988","unstructured":"Kagimoto M, Winter JSD, Kagimoto K, Simpson ER, Waterman MR. Structural characterization of Normal and mutant human steroid 17\u03b1- hydroxylase genes: molecular basis of one example of combined 17\u03b1- hydroxylase\/17,20 Lyase deficiency. Mol Endocrinol. 1988;2(6):564\u201370.","journal-title":"Mol Endocrinol"},{"issue":"8","key":"901_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1172\/JCI103181","volume":"34","author":"WR Eberlein","year":"1955","unstructured":"Eberlein WR, Bongiovanni AM. Partial characterization of urinary adrenocortical steroids in adrenal hyperplasia. J Clin Invest. 1955;34(8):1337\u201343.","journal-title":"J Clin Invest"},{"issue":"4","key":"901_CR15","first-page":"249","volume":"86","author":"L Wilkins","year":"1950","unstructured":"Wilkins L, Lewis RA, Klein R, Rosemberg E. The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp. 1950;86(4):249\u201352.","journal-title":"Bull Johns Hopkins Hosp"},{"key":"901_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jsbmb.2019.01.018","volume":"190","author":"J Rege","year":"2019","unstructured":"Rege J, Turcu AF, Else T, Auchus RJ, Rainey WE. Steroid biomarkers in human adrenal disease. J Steroid Biochem. 2019;190:273\u201380.","journal-title":"J Steroid Biochem"},{"key":"901_CR17","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1194\/jlr.R016675","volume":"52","author":"WL Miller","year":"2011","unstructured":"Miller WL, Bose HS. Early steps in steroidogenesis: intracellular cholesterol trafficking. J Lipid Res. 2011;52:2111\u201335.","journal-title":"J Lipid Res"},{"key":"901_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1194\/jlr.R009548","volume":"52","author":"FD Porter","year":"2011","unstructured":"Porter FD, Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res. 2011;52:6\u201334.","journal-title":"J Lipid Res"},{"issue":"9","key":"901_CR19","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.metabol.2013.04.003","volume":"62","author":"MJ Gouveia","year":"2013","unstructured":"Gouveia MJ, Brindley PJ, Santos LL. Correia da Costa JM, Gomes P, Vale N. mass spectrometry techniques in the survey of steroid metabolites as potential disease biomarkers: a review. Metabolism. 2013;62(9):1206\u201317.","journal-title":"Metabolism."},{"issue":"1","key":"901_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.mce.2012.12.026","volume":"371","author":"KM Wooding","year":"2013","unstructured":"Wooding KM, Auchus RJ. Mass spectrometry theory and application to adrenal diseases. Mol Cell Endocrinol. 2013;371(1):201\u20137.","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"901_CR21","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1210\/jc.2006-2890","volume":"92","author":"N Janzen","year":"2007","unstructured":"Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2007;92(7):2581\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"901_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1203\/PDR.0b013e3181aa3777","volume":"66","author":"E Schwarz","year":"2009","unstructured":"Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, et al. Use of steroid profiling by UPLC-MS\/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res. 2009;66(2):230\u20135.","journal-title":"Pediatr Res"},{"key":"901_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jchromb.2012.12.003","volume":"927","author":"F Gosetti","year":"2013","unstructured":"Gosetti F, Mazzucco E, Gennaro MC, Marengo E. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review J Chromatogr B. 2013;927:22\u201336.","journal-title":"A review J Chromatogr B"},{"issue":"3","key":"901_CR24","first-page":"186","volume":"1","author":"J Fiet","year":"2017","unstructured":"Fiet J, Le Bouc Y, Gu\u00e9chot J, H\u00e9lin N, Maubert M-A, Farabos D, et al. A liquid chromatography\/tandem mass Spectometry profile of 16 serum steroids, including 21-Deoxycortisol and 21-Deoxycorticosterone, for management of congenital adrenal hyperplasia. J Endocrinol. 2017;1(3):186\u2013201.","journal-title":"J Endocrinol"},{"issue":"12","key":"901_CR25","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1530\/EC-18-0453","volume":"7","author":"SR Dahl","year":"2018","unstructured":"Dahl SR, Nermoen I, Br\u00f8nstad I, Husebye ES, L\u00f8v\u00e5s K, Thorsby PM. Assay of steroids by liquid chromatography-tandem mass spectrometry in monitoring 21-hydroxylase deficiency. Endocr Connect. 2018;7(12):1542\u201350.","journal-title":"Endocr Connect"},{"issue":"4","key":"901_CR26","first-page":"1511","volume":"86","author":"JB Quintos","year":"2001","unstructured":"Quintos JB, Vogiatzi MG, Harbison MD, New MI. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2001;86(4):1511\u20137.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00901-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00901-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00901-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T13:03:59Z","timestamp":1637845439000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00901-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00901-8","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval number: TJ-IRB20180703) and adhered to the tenets of the Declaration of Helsinki. Informed written consent was obtained from the parents of the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish was obtained from each participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}